CytomX Therapeutics (CTMX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

Analysts are showing growing confidence in European and Chinese tech stocks as they outperform the S&P 500 (SPX). Many ...

Quality dividend stocks yielding 7% and more are the best ideas for many investors now. These five are too cheap to ignore ...

Quality dividend stocks yielding 7% and more are the best ideas for many investors now. These five are too cheap to ignore any longer. You can follow him investing $500,000 of his own money on our top ...

Durect (DRRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

PennantPark (PFLT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Solid Biosciences (SLDB – Research Report). The company’s ...